The Green Cross Corporation

Daewoong Pharmaceutical Co., Ltd.

Mogam Institute for Biomedical Research

Legochem Biosciences, Inc.

Soongyu Choi

Hee Jeong Seo

Min Ju Kim

Eun-Jung Park

Younggyu Kong

So Ok Park

Kwang-Seop Song

Mi-Soon Kim

Suk Ho Lee

Kisoo Park

Ickhwan Son

Man-Young Cha

Hyun Jung Kim

Min Woo Lee

Myung Eun Jung

Hyunku Kang

Kinam Lee

Jun Sung Lee

Sang-ho Ma

Se-Hwan Park

Sujeong Kim

Kyuhyun Lee

Hyung-Kwon Lim

Mijung Lee

Dong Hyuk Jang

Dong-Sik Kim

Eun Jung Song

Hee-kyoon Yoon

Young Seoub Park

Dong Ho Hong

Jongwha Won

Eun-Hee Lee

Kisu Kim

Misuk Kang

Ji-sung Yoon

Sang Mi Kang

Jangwon Hong

Jae Hyun Park

Yong Zu Kim

Ho Young Song

Sung Ho Woo

Jae Eun Kim

Tae Kyo Park

Sang Eun Chae

Young Lag Cho

Dae Yon Lee

Sung Yoon Baek

Jae Chan Park

Yoo Hoon Kim

Miyoung Oh

Jungsub Choi

Kwang Seop Song

Jae Yeon Kim

So-Hyun Yoon

Ji-Sung Yoon

Hee-Kyoon Yoon

The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.

Method for producing diphenylmethane derivative

The present invention relates to an antibody specifically bound to mesothelin (MSLN), a nucleic acid encoding the antibody, a vector and a host cell including the nucleic acid, a method for producing the antibody, and a pharmaceutical composition for treating cancer or tumor including the antibody as an active ingredient. The antibody specifically bound to the mesothelin according to the present invention has high affinity and specificity to an antigen, such that it is possible to develop an antibody effectively usable for treatment or diagnosis of cancer or tumor diseases.

Anti-mesothelin antibody and composition comprising the same

The present invention relates to an antibody specifically binding to glypican 3 (GPC3), a nucleic acid encoding the antibody, a vector and a host cell containing the nucleic acid, a method of preparing the antibody, and a pharmaceutical composition for treating cancer or tumor, containing the antibody as an active ingredient. The antibody specifically binding to glypican 3 according to the present invention may be effectively used to treat cancer or tumor, particularly, hepatocellular carcinoma due to high affinity and specificity to glypican 3.

Anti-glypican 3 antibody and pharmaceutical composition containing the same

Provided is pyrazole derivatives as a TNIK (Traf2- and NCK-interacting kinase), IKK&#x3b5; (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the pyrazole derivative according to the present invention effectively inhibits TNIK, IKK&#x3b5; and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.

Pyrazole derivatives as TNIK, IKK&#x3f5; and TBK1 inhibitor and pharmaceutical composition comprising same

Provided are 7-azaindole or 4,7-diazaindole derivatives as an IKK&#x3b5; (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor. The 7-azaindole or 4,7-diazaindole derivative effectively inhibits IKK&#x3b5; and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.

7-azaindole or 4,7-diazaindole derivatives as IKK&#x3f5; epsilon and TBK1 inhibitor and pharmaceutical composition comprising same

The present invention relates to a novel crystalline form of 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and a pharmaceutical composition containing the same. The novel crystalline form of a compound according to the present invention exhibits excellent stability even in high-temperature and humidity environments, and thus can be favorably used to prevent or treat diseases, such as thrombosis, myocardial infarction, atherosclerosis, inflammation, stroke, angina pectoris, restenosis after angioplasty, and thromboembolism.

Crystalline form of 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition comprising same

Provided is a compound of formula (I) as a TNIK (Traf2- and NCK-interacting kinase), IKK&#x3b5; (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the compound according to the present invention effectively inhibits TNIK, IKK&#x3b5; and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.

Compounds as TNIK, IKK&#x3b5; and TBK1 inhibitors and pharmaceutical composition comprising same

A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.

Diphenylmethane derivatives as SGLT2 inhibitors

The present invention relates to a method for dual inhibition of sodium-dependent glucose cotransporter 1 (SGLT1) and sodium-dependent glucose cotransporter 2 (SGLT2) present in the intestine and kidney by using the compound of formula I or a pharmaceutically acceptable salt or a prodrug thereof: wherein ring A, ring B, X and Y have the same meanings as defined in the specification.

Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives

Disclosed is a novel C-aryl ansa compound having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. Also provided are a method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound.

[object Object]

Growing community of inventors

Yongin-si, South Korea

Soongyu Choi